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Prompt Reversal of Airway Obstruction Secondary to Angiotensin Converting Enzyme Inhibitor (ACEI)
Induced Angioedema by Ecallantide: A Case Report
J.R. Cohn, C. McDaniel, N. Richards, C. Au, M. Baram
Thomas Jefferson University and Hospitals, Philadelphia, PA 19107
INTRODUCTION

• Fatal airway obstruction from ACEI angioedema has been described
but effective therapy has not been established. Intubation is
sometimes required for progressive airway compromise. Ecallantide is
a kallikrein pathway blocker and may offer benefit in reversing ACEI
induced angioedema.

CONCLUSION

RESULTS
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CLINICAL COURSE AND OUTCOME
Case

• A 54 year old African-American male with a history of hypertension treated
with lisinopril daily, remote cocaine abuse associated myocardial infarction,
seizures and prostate cancer, presented with a 2 day history of facial and throat
swelling along with dysphagia. He was treated in the emergency department
with intravenous methylprednisolone, epinephrine and diphenhydramine. He
was admitted, but angioedema progressed overnight, confirmed by
laryngoscopy. ICU transfer and intubation was undertaken the next morning
for airway protection. Tryptase level was 2 ng/ml. C3 and C4 and routine
chemistries were normal. Ecallantide 30mg was administered subcutaneously
at 1014 hours.
• Medications: Lisinopril 10mg daily, tamsulosin.
• Family History: No history of angioedema. Parents deceased.

• Patient improved over the day and self-extubated prior to 1800 hours. He had
no dysphagia or difficulty with respiration and was discharged the next
morning.
•ACEI angioedema is a recognized complication of ACEI treatment that can
occur months to years after starting therapy. The incidence is thought to be 0.10.5% (Warner. Ann Pharmacother 2000; 34: 526). Fatalities from airway
obstruction are described (Dean. J Forensic Sci 2001; 46: 1239). Angiotensin
converting enzyme is an important enzyme for degradation of bradykinin.
Ecallantide selectively and reversibly inhibits plasma kallikrein, preventing
bradykinin generation. This case suggests that ecallantide may indeed be
effective in reversing ACEI induced angioedema, even in patients requiring
intubation for airway protection.
•This presentation was supported in part by Dyax, Inc.

• Social history. Denies current alcohol or recreational drug use.

• The mechanism of ACEI angioedema is thought to be from blockade of
angiotensin converting enzyme, the major enzyme for degradation of
bradykinin.
• Bradykinin and substance P have been linked to the pathogenesis of ACEI
induced angioedema. Angiotensin converting enzyme (ACE) is a kinase that
breaks down bradykinin 4. The inhibition of ACE therefore leads to the
inhibition of bradykinin catabolism. Bradykinin formation causes
vasodilatation and increased vascular permeability by interaction with B-2
receptors. The inhibition of bradykinin catabolism thus leads to angioedema.
• Antihistamines, corticosteroids and epinephrine are ineffective in acute attacks
of non-allergic angioedema. The mainstay of treatment currently is airway
protection and supportive care. Theoretically, glucocorticoids could lead to a
decrease in mucosal swelling. However, there is no demonstrated beneficial
effect in patients with angioedema. Inhaled epinephrine may also be effective
in laryngeal angioedema 8.
• Ecallantide is approved treatment of hereditary angioedema. It selectively and
reversibly inhibits plasma kallikrein, preventing bradykinin generation. It is
theorized that ecallantide can be used to treat other forms of kallikrein
dependant angioedema.
• The length of hospitalization for patients with ACEI induced angioedema has
ranged from 2 days to 4.8 days 5, 9. Our patient self-extubated a few hours after
emergent intubation and was discharged the next day after he remained stable
overnight and without distress.
• This case suggests that ecallantide may indeed be effective in the cessation of
ACEI induced angioedema. Additional randomized studies are underway to
confirm these findings

• Review of Systems: Remarkable for hypertension. On disability for back and
knee problems.
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